RT Journal Article
SR Electronic
T1 Prothrombin complex concentrate in the management of major bleeding induced by oral anticoagulant therapy
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 213
OP 217
DO 10.15537/smj.2022.43.2.20210736
VO 43
IS 2
A1 AlSheef, Mohammed
A1 Kullab, Ghaydaa
A1 Alajmi, Modhi
A1 Aldhaheri, Ruba
A1 Al Baqmi, Sultan
A1 Alajlan, Haya
A1 Zaidi, Abdul Rehman Z.
A1 Abu-Shaheen, Amani
YR 2022
UL http://smj.org.sa/content/43/2/213.abstract
AB Objectives: To share clinical data on the efficacy of 4F-PCC in the treatment of major bleeding caused by warfarin, dabigatran, and rivaroxaban.Methods: This is a retrospective study of patients admitted to King Fahad Medical City, Riyadh, Saudi Arabia with major bleeding caused by oral anticoagulants and treated with 4-factor prothrombin complex concentrate (4F-PCC). The International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria were used to evaluate the effectiveness of PCCs.Results: A total of 22 patients were included in the study. Ten of the events were caused by gastrointestinal bleeding (46%). In the majority of patients, anticoagulation was prescribed for stroke prevention, atrial fibrillation, and venous thromboembolism. The median international normalized ratio was significantly lower before and after PCC administration (p<0.001). In patients treated with 4-factor PCC, the rate of thromboembolic events was 0%. The hemostatic effectiveness of PCC was effective in 19 patients. During treatment, no clinically significant bleeding complications occurred.Conclusion: Prothrombin complex concentrate can effectively reverse the effects of warfarin and rivaroxaban in patients with major bleeding, but only partially reverses the effect of dabigatran.